Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial by Plomgaard, Anne M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the
SafeBoosC II trial
Plomgaard, Anne M; Alderliesten, Thomas; Austin, Topun; van Bel, Frank; Benders, Manon; Claris,
Olivier; Dempsey, Eugene; Fumagalli, Monica; Gluud, Christian; Hagmann, Cornelia; Hyttel-Sorensen,
Simon; Lemmers, Petra; van Oeveren, Wim; Pellicer, Adelina; Petersen, Tue H; Pichler, Gerhard;
Winkel, Per; Greisen, Gorm
DOI: https://doi.org/10.1371/journal.pone.0173440
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-137764
Published Version
 
 
Originally published at:
Plomgaard, Anne M; Alderliesten, Thomas; Austin, Topun; van Bel, Frank; Benders, Manon; Claris,
Olivier; Dempsey, Eugene; Fumagalli, Monica; Gluud, Christian; Hagmann, Cornelia; Hyttel-Sorensen,
Simon; Lemmers, Petra; van Oeveren, Wim; Pellicer, Adelina; Petersen, Tue H; Pichler, Gerhard; Winkel,
Per; Greisen, Gorm (2017). Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the
SafeBoosC II trial. PLoS ONE, 12(3):e0173440.
DOI: https://doi.org/10.1371/journal.pone.0173440
RESEARCH ARTICLE
Early biomarkers of brain injury and cerebral
hypo- and hyperoxia in the SafeBoosC II trial
Anne M. Plomgaard1*, Thomas Alderliesten2, Topun Austin3, Frank van Bel2,
Manon Benders2, Olivier Claris4, Eugene Dempsey5, Monica Fumagalli6, Christian Gluud7,
Cornelia Hagmann8, Simon Hyttel-Sorensen1, Petra Lemmers2, Wim van Oeveren9,
Adelina Pellicer10, Tue H. Petersen11, Gerhard Pichler12, Per Winkel7, Gorm Greisen1
1 Department of Neonatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark,
2 University Medical Center Utrecht, Wilhelmina Children’s Hospital, Utrecht, The Netherlands, 3 Rosie
Hospital Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 4 Department
of Neonatology, Hospices Civils de Lyon, Claude Bernard University, Lyon, France, 5 INFANT Centre,
University College Cork, Cork, Ireland, 6 NICU,Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, Università degli Studi di Milano, Milan, Italy, 7 Copenhagen Trial Unit, Centre for Clinical
Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 8 Clinic of
Neonatology, University of Zurich, Zurich, Switzerland, 9 Haemoscan B.V., Groningen, The Netherlands,
10 Department of Neonatology, La Paz University Hospital, Madrid, Spain, 11 Research Unit on Brain Injury
Neurorehabilitation Copenhagen, Department of Neurorehabilitation, TBI Unit, Rigshospitalet, Copenhagen
University Hospital, Hvidovre, Denmark, 12 Department of Pediatrics, Research Unit for Neonatal Micro- and
Macrocirculation, Medical University of Graz, Graz, Austria
* amplomgaard@gmail.com
Abstract
Background
The randomized clinical trial, SafeBoosC II, examined the effect of monitoring of cerebral oxy-
genation by near-infrared spectroscopy combined with a guideline on treatment when cere-
bral oxygenation was out of the target range. Data on cerebral oxygenation was collected in
both the intervention and the control group. The primary outcome was the reduction in the bur-
den of cerebral hypo- and hyperoxia between the two groups. In this study we describe the
associations between the burden of cerebral hypo- and hyperoxia, regardless of allocation to
intervention or control group, and the biomarkers of brain injury from birth till term equivalent
age that was collected as secondary and explorative outcomes in the SafeBoosC II trial.
Methods
Cerebral oxygenation was continuously monitored during the first 72h of life in 166 ex-
tremely preterm infants. Cranial ultrasound was performed at day 1,4,7,14, and 35 and at
term. Electroencephalogram (EEG) was recorded at 64h. Blood-samples taken at 6 and 64
hours were analysed for the brain injury biomarkers; S100beta, brain-fatty-acid-binding-pro-
tein, and neuroketal. All analyses were conducted post hoc.
Results
Significantly more infants with a cerebral burden of hypoxia within the 4th quartile versus
infants within quartile 1–3 were diagnosed with severe intracranial haemorrhage (11/39 ver-
sus 11/117, p = 0.003), had low burst rate on EEG (12/28 versus 21/103, p = 0.015), or died
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(14/41 versus 18/123, p = 0.006), whereas none of these events were significantly associ-
ated with cerebral hyperoxia. The blood biomarkers were not significantly associated with
the burden of cerebral hypo- or hyperoxia.
Conclusions
The explorative analysis showed that early burden of cerebral hypoxia, but not hyperoxia
was significantly associated with low brain electrical activity and severe intracranial haemor-
rhage while none of the three blood biomarkers were associated with the burden of either
cerebral hypo- or hyperoxia.
Introduction
Extremely preterm infants have an immature cardiorespiratory system and cerebral autoregula-
tion can be impaired, especially during the first days of life [1,2]. This makes the developing brain
of the preterm infant susceptible to fluctuations in the cerebral blood flow (CBF) [3] and may
cause episodes of cerebral hypo- and hyperoxia. Near-infrared spectroscopy (NIRS) is a non-inva-
sive method for estimating tissue oxygenation. NIRS measures the ratio of the concentrations of
oxygenated haemoglobin to total haemoglobin on an absolute scale with a range of 0% to 100%
[4]. Changes in cerebral NIRS-values are correlated to CBF [5]. A number of biomarkers–charac-
teristics that is objectively measured and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a therapeutic intervention [6]—may be
present if the brain is suffering from hypo- or hyperoxia. Severe intraventricular haemorrhage
(IVH grade III) and periventricular haemorrhagic infarction (PVHI) mainly develop within the
first 3 days of life [7], during the period of transition from intra- to extra-uterine life when the
brain is especially vulnerable. Low cerebral oxygenation, as estimated by NIRS, during this transi-
tion has been associated with higher grades of intraventricular haemorrhage and lower 2-year
developmental quotients [8–10]. In addition high values of NIRS in animal studies are associated
with brain injury [11], as confirmed in human asphyxiated term new-borns [12]. Cerebral NIRS
monitoring is currently used in some neonatal intensive care units as part of the standard of care
for extremely preterm infants and infants with hypoxic-ischemic encephalopathy. Yet it remains
to be determined if monitoring cerebral oxygenation combined with clinical interventions when
cerebral oxygenation levels are out of range actually prevents cerebral injury, improves neurologi-
cal outcome, and/or increases the survival of the extremely preterm infants [13].
The phase II randomized clinical trial, SafeBoosC II, demonstrated that it is possible to
reduce the burden of cerebral hypoxia during the first 72 hours of life [14]. The SafeBoosC II
study was, however, not powered to detect differences in clinical outcomes [15]. In the present
post hoc analysis, we use the SafeBoosC II data to explore the association between the burden
of cerebral hypo- and hyperoxia regardless of trial allocation to intervention or control group,
and the secondary and explorative outcomes of the trial (all being potential biomarkers of
brain injury or death): namely serial cranial ultrasound (cUS), electroencephalographic (EEG)
measures, and blood molecular markers.
Patients and methods
Infant characteristics and study design
SafeBoosC II is a multicentre randomised clinical feasibility trial [15]. A total of 166 extremely
preterm infants were included in the SafeBoosC II study before 3 hours of age: 86 infants were
Cerebral hypoxia and early markers of brain injury
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randomised to the experimental group (cerebral NIRS monitoring in combination with an evi-
dence based intervention guideline [16] for NIRS values out of range (55–85%)) and 80 infants
to the control group (blinded collection of NIRS values combined with treatment as usual).
The inclusion criteria were infants born more than 12 weeks before term (gestational age<27
weeks and six days) with a decision to provide full life support and the possibility to start cere-
bral NIRS monitoring within three hours after birth. Written informed consent from the
parents was mandatory before inclusion and randomisation. The randomisation was web
based and handled by The Copenhagen Trial Unit. The generated allocation sequence of 1:1
with block sizes 4 and 6 in random order concealed for the investigators. The intervention
period was 72 hours. The 2y-followup of the infants is on going. The infants were recruited
from 8 European countries each represented by one neonatal intensive care unit (June 2012 to
December 2013). The trial is registered at ClinicalTrial.gov, NCT01590316, the protocol is
available in full at http://www.safeboosc.eu.
The burden of cerebral hypo- and hyperoxia
The primary outcome of the SafeBoosC II trial was the burden of hypo- and hyperoxia. This
was calculated as the time spent below or above the target limits multiplied by the mean devia-
tion from the lower (55%) or the upper limit (85%) during the first 72 hours of life, expressed
in percentage hours (%hours). The burden was computed from un-edited NIRS-values and
extrapolated to 72 hours, without knowledge of any other outcomes of the trial [14].
Cranial ultrasound
On day 1 (anytime during the first 24 hours of life), 4 (± 1), 7 (± 1), 14 (± 1), and 35 (± 1) and
at term equivalent age (week 38 to 44) standardized cUS (6 coronal and 5 sagittal images
through the anterior fontanel and one through the mastoid window) was performed. The
images were anonymised and uploaded to a central server. The images were centrally analysed
by two experts (CH and MB) using the software program OsiriX version 6.0 (Pixmeo, Geneva,
Switzerland). The process of the central scoring is described in detail elsewhere [17]. IVH
grade III, PVHI, post haemorrhagic ventricular dilatation, porencephalic cysts, cystic periven-
tricular leukomalacia, cerebral atrophy at term, stroke and cerebellar haemorrhage at one
or more of the scans were classified as severe brain injury, and thereby as severe adverse
outcome.
Electroencephalogram
EEG was analysed in 133 infants, the median age at EEG-recording was 65 hours postnatal and
the median time of recording was 2 hours [18]. Electrodes were placed at P3 and P4 position
according to the international 10-20-system. Needle, disc or hydrogel electrodes were used
according to local practice. The electrode impedance was less than 20kO during the record-
ing. If the child was treated with morphine, other opioids, or sedative medications this was
documented.
All EEG analysis was performed in Matlab version R2014b using custom build programmes
(MathWorks, Natick, Massachusetts, USA), without knowledge of the medical history of the
infant. The analysis of the EEGs is described in detail elsewhere [18].
The raw EEG was band pass filtered (0.5–30 Hz) using a zero phase filter and converted
into range-EEG (rEEG) [19]. Artefacts in the rEEG were independently visually identified by
two of the authors (GG and AMP) blinded to the clinical history of the infant. The EEG analy-
sis was conducted on the remaining artefact-free data.
Cerebral hypoxia and early markers of brain injury
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Burst rate was calculated as the number of bursts per minute. A burst was defined as nested
(high frequency) oscillations within large slow-wave depolarisations using an extraction algo-
rithm based on the co-occurrence of a slow (0.5–2 Hz) wave and higher (8–22 Hz) frequency
oscillation, as described by Hartley et al. [20]. Consecutive events occurring within 0.5 seconds
of one another were counted as one and events of duration less than 4/22 of a second were dis-
counted [20]. Burst rates were significantly affected (decreased burst rate) by the use of mor-
phine and EEG-recordings with an online filtration at 2–15 Hz (decreased burst rate) [18].
Therefore the burst rates were adjusted for these variables. Adjusted burst rate within the 1st
quartile was considered an adverse outcome.
Spectral-analyses were conducted using Matlab routines (Neurospec 2.0, Neurospec.org).
The EEG data was segmented into epochs of 2 seconds with an overlap of 50% (1 second).
After fast Fourier transformation the 95% spectral edge frequency (SEF95) for each infant was
defined as the frequency between 0.5 and 30 Hz, below which 95% of the power was present.
SEF95 was significantly affected by the EEG sampling frequency (high sampling frequency
higher SEF95) [18]. Therefore the SEF95 was adjusted for this. Adjusted SEF95 within the 1st
quartile was considered an adverse outcome.
Blood biomarkers
At the age of 6 and 64 hours (±1 h) 1 ml of blood was drawn from 123 infants with an indwell-
ing arterial or venous line [18]. After inclusion of the last patient, the samples were shipped
and analysed centrally (HaemoScan, Groningen, The Netherlands) without knowledge of the
medical history of the infant. S100beta (50 μl) was assessed by ELISA: clone 1B2 monoclonal
antibody (Abnova, Taipei, Taiwan) and biotinylated clone 8B10 (Hytest, Turku, Fi). Intra-
assay variance is 4.6% and the lower level of quantification (LLOQ) is 39 pg/ml. Brain fatty
acid binding protein (BFABP) (50 μl) was determined by ELISA with BFABP polyclonal capture
antibodies and monoclonal detection antibody (HaemoScan). Intra-assay variance is 6.4% and
the LLOQ is 150 pg/ml. Neuroketal (60 μl) was performed by competitive enzyme immunoas-
say (HaemoScan). Intra-assay variance is 10% and the LLOQ is 4.1 pg/ml. The laboratory anal-
yses are described in detail elsewhere [18]. An increase in the biomarker concentration from 6
to 64 hours was considered as a marker of potential cerebral injury during the intervention
period, therefore and adverse outcome was defined as an increase in the absolute value of the
biomarker concentration from 6 hours to 64 hours within the 4th quartile.
Statistics
The median and inter quartile range of burden of cerebral hypo- and hyperoxia was deter-
mined. The infants were divided in groups according to a burden within or below the 4th quar-
tile of the burden of cerebral hypo- and hyperoxia, respectively. The infant characteristics were
compared between the burden-groups using the chi-square test or independent t-test as appro-
priate. Odds ratios with 95% confidence intervals were determined for adverse outcomes for
infants within the 4th quartile of the burden of hypo- or hyperoxia versus infants in quartile
1–3. Thereafter univariate correlation analysis was conducted to determine the patient charac-
teristics associated with the composite outcome of severe brain injury or death. Finally, a mul-
tiple logistic regression was used with the composite outcome as dependent variable, centre,
gestational age above or below 26 weeks (the stratification variables used in the randomized
SafeBoosC II trial), and intervention as forced entry independent variables, and the patient
characteristics which had significant correlation to the composite outcome as independent
variables in a backward stepwise elimination procedure (P-out 0.1).
Cerebral hypoxia and early markers of brain injury
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The between twins inter-cluster correlation for the burden of hypo-and hyperoxia was low
(0.02) [14]. Therefore, there was no need to exclude one infant from each twin-cluster thus
data from all infants were included in the analysis.
None of the analyses reported here were specified in the SafeBoosC-II study protocol. The
dichotomisation between one quartile and the three other quartiles was copied from previous
work on biomarkers in our group [21], and chosen before any correlations were calculated.
The statistics was performed using IBM SPSS Statistics for Windows Version 20.0
(Armonk, New York, USA).
Ethics
The SafeBoosC phase II trial was approved by each hospital’s research ethics committee
(Hopital Femme Mere Enfants, Lyon, France; Rigshospitalet, Copenhagen, Denmark; La Paz
University Hospital, Madrid, Spain; Cork University Maternity Hospital, Cork, Ireland; Wil-
helmina Children’s Hospital, Utrecht, The Netherlands; Medical University of Graz, Graz,
Austria; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; and
Rosie Hospital, Cambridge University Hospitals, United Kingdom), and where required (Aus-
tria, Denmark, and France) by the competent authority responsible for medical devices. Writ-
ten informed parental consent was mandatory before inclusion in the trial. The trial was
conducted in compliance with the guidelines of the Declaration of Helsinki in its latest form
and the International Conference on Harmonisation good clinical practice guidelines.
Results
One-hundred-and-sixty-six infants were included in the SafeBoosC II trial, Fig 1. Cerebral
oximetry data was missing for two infants due to technical issues (n = 1) and withdrawal of
consent (n = 1).
The median (min—max) burden of cerebral hypoxia was 30.6%hours (0.7–803.9). The lim-
its for hypoxia quartile 4 were 99.3–803.9%hours and for quartile 1–3; 0.7–99.2%hours. The
median (min—max) burden of cerebral hyperoxia was 1.2%hours (0.0–223.0). The limits for
quartile 4 were 14.2–223.0%hours and for quartile 1–3; 0.0–14.1%hours. As expected accord-
ing to the primary result of the SafeBoosC II trial [14], there were significantly fewer infants
form the intervention group with a burden of hypoxia in the 4th quartile, than in quartile 1–3,
whereas the burden of cerebral hyperoxia within the 4th quartile versus quartile 1–3, was unaf-
fected by allocation in the SafeBoosC trial, Table 1. Male sex was associated with less cerebral
hypoxia and more cerebral hyperoxia. Furthermore, gestational age was positively associated
with cerebral hyperoxia whereas the other baseline characteristics were not associated with
either cerebral hypo- or hyperoxia.
Serial ultrasound scans of 155 infants were available for evaluation by central reading.
Twenty-seven (27/155) had severe brain injury, of which 22 had IVH grade III or PVHI. The
remaining five infants had stroke (n = 2), cerebral atrophy (n = 2), or cerebellar haemorrhage
(n = 1). Cerebral hypoxia was significantly associated with severe brain injury and death,
Table 2. There was no significant association between cerebral hyperoxia and severe brain
injury and death, Table 3. Cerebral hypoxia was significantly associated with early occurrence
(day 1 to 4) of severe intracranial haemorrhages whereas there was no association between
cerebral hypoxia and later occurrence (day 5 to day 14) of severe intracranial haemorrhages,
Table 2. Cerebral hypoxia was also significantly associated with low EEG burst rates at 64
hours of age whereas there was no association between cerebral hypoxia and SEF95 at 64
hours of age. Of the 14 infants with early severe IVH ten (10) infants had EEG measurement
and of these five (5) infants had burst rates within the 1st quartile, for the infants without severe
Cerebral hypoxia and early markers of brain injury
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haemorrhages the number of recorded EEGs was 115 and hereof 26 had burst rates within the
1st quartile (chi-square analysis between groups p = 0.12). The three plasma-biomarker-levels
were not associated with cerebral hypoxia, Table 2. Cerebral hyperoxia was not associated with
EEG burst rate, SEF95 or plasma biomarkers, Table 3. The odds ratios (ORs) and 95% confi-
dence interval for adverse outcomes are illustrated in Figs 2 and 3.
Correlation analyses of the following variables showed a significant correlation (p<0.05)
between gestational age, birth weight, clinical chorioamnionitis, surfactant, mechanical venti-
lation, use of vasopressors, blood transfusions, and the burden of cerebral hypoxia within the
4th quartile on one hand and the composite outcome of severe brain injury or death on the
other. These variables were included in the multiple logistic regression model with backward
stepwise elimination. As described in the methods, centre, gestational age below 26 weeks, and
intervention were forced-entry variables in the model. The following variables remained statis-
tically significant: intervention (OR (95% CI) 0.29 (0.12–0.69; p = 0.003,)), gestational age
below 26 weeks (3.33 (1.38–8.06; p = 0.007)), use of vasopressors (3.26 (1.26–8.44; p = 0.014)),
and blood transfusion (2.97 (1.22–7.23; p = 0.016)). There was no centre-effect.
Fig 1. Flowchart. Flow of participants through the SafeBoosC II study.
https://doi.org/10.1371/journal.pone.0173440.g001
Cerebral hypoxia and early markers of brain injury
PLOS ONE | https://doi.org/10.1371/journal.pone.0173440 March 22, 2017 6 / 15
Discussion
This post hoc analysis shows that early burden of cerebral hypoxia, but not hyperoxia, is asso-
ciated with a reduction of brain electrical activity, severe brain injury (especially early IVH
grade III and PVHI), and death. There were no significant associations between the burden of
cerebral hypo- and hyperoxia and the three blood biomarkers. Multiple logistic regressions
showed significant associations between intervention, gestational age below 26 weeks, use of
vasopressors, and blood transfusion on one hand and the composite adverse outcome severe
brain injury or death on the other.
Low cerebral oxygenation has previously been associated with IVH and lower developmen-
tal quotients at 2-year follow up [8–10]. In a study by Noori et al, involving 22 extremely pre-
term infants, lower levels of cerebral oxygenation, cardiac output, and cerebral hypoperfusion
were found prior to the development of IVH II and PVHI [8]. In term piglet models, however,
while low cerebral oxygenation when accompanied by low cerebral blood flow caused perma-
nent brain damage, prolonged cerebral hypoxia alone seemed to be of less importance [22,23].
Piglets had to be exposed to cerebral hypoxia as low as 30–35% for several hours before signifi-
cant histological damage appeared [23].
In the present analysis the burden of cerebral hypoxia was associated with decreased EEG
burst rates. This is in agreement with a previous demonstration of an association between low
cerebral blood flow and suppressed EEG in preterm infants [24]. EEG burst rate is decreased
in infants with severe IVH [25,26] and suppressed EEG is correlated to adverse developmental
outcome [27,28]. In the present analysis we did not find significantly more infants with low
burst rates and early severe IVH grade III or PVHI.
Table 1. Baseline characteristics and treatment during the first 72 hours of life according to burden of cerebral hypo- or hyperoxia split in the
three lowest quartiles and the highest quartile.
Burden of hypoxia Burden of hyperoxia
Quartile 1 to 3 Quartile 4 Quartile 1 to 3 Quartile 4
n = 123 n = 41 P-value n = 123 n = 41 P-value
Baseline characteristics
Gestational age (week), mean (SD) 26.4 (1.2) 26.5 (1.5) 0.78 26.3 (1.3) 27.7 (1–0) 0.35
Gestational age below 26 weeks 38 (31) 14 (34) 0.7 42 (34) 10 (24) 0.025
Birth weight (gram), mean (SD) 847 (211) 875 (207) 0.47 849 (208) 872 (216) 0.54
Male sex 65 (53) 13 (32) 0.02 53 (43) 25 (61) 0.047
Twins 21 (17) 12 (29) 0.09 23 (19) 10 (24) 0.43
Antenatal steroids full course 82 (67) 31 (78) 0.2 88 (72) 25 (61) 0.18
Prolonged rupture of membranes 40 (33) 17 (36) 0.21 42 (34) 15 (38) 0.72
Maternal chorioamnionitis 6 (5) 5 (13) 0.1 9 (8) 2 (5) 0.59
APGAR-score <5 points at 5 minutes 21 (17) 8 (20) 0.69 20 (16) 9 (23) 0.38
Umbilical arterial pH, mean (SD) 7.32 (0.1) 7.31 (0.1) 0.62 7.32 (0.1) 7.29 (0.1) 0.13
SafeBoosC II intervention group 74 (60) 12 (29) 0.001 67 (54) 19 (46) 0.37
Treatment during the first 72h of life
Surfactant treatment 90 (73) 35 (85) 0.11 90 (73) 35 (85) 0.11
Mechanical ventilation 79 (64) 30 (73) 0.29 80 (65) 29 (70) 0.5
Patent ductus arteriosus treatment 17 (14) 4 (10) 0.52 15 (12) 6 (15) 0.71
Use of vasopressors/inotropes 22 (18) 16 (40) 0.004 29 (24) 9 (22) 0.79
Any red blood cell transfusion 31 (26) 18 (45) 0.025 41 (35) 8 (20) 0.07
Corticosteroids 4 (3) 4 (10) 0.1 6 (5) 2 (5) 0.99
Values are numbers (percentages) unless stated otherwise. P-values have not been corrected for multiple comparisons.
https://doi.org/10.1371/journal.pone.0173440.t001
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The three blood biomarkers measured in the SafeBoosC II trial were not significantly asso-
ciated with either cerebral hypo- or hyperoxia. We did not register whether the samples were
drawn from arterial or venous line, therefore we are unable to determine whether the concen-
trations of the blood biomarkers differ between arterial and venous blood.
S100beta is a calcium binding protein present in high concentration in Schwann cells and
astrocytes [29] and is released to the systemic circulation after cerebral damage. S100beta is an
established marker of brain injury in adult trauma patients [30] and the levels of S100beta in
blood and urine from term and preterm infants has been associated with the severity of both
hypoxic ischemia and IVH [31–33]. And in a study including 64 term and late preterm infants
the levels of S100beta was significantly negatively correlated to NIRS-values [34]. However a
study by Rogers et al [35] including 130 extremely preterm infants reporting no associations
between the S100beta levels and severe intracranial haemorrhages. S100Beta has also been
investigated as a potential biomarker of brain injury in paediatric patients undergoing cardiac
surgery–the infants with unfavourable neurological outcome 12 months after surgery had sig-
nificantly lower cerebral NIRS values during surgery, whereas the levels of S100Beta did not
differ [36]. We evaluated the effects of the accumulated burden of hypoxia during the first 72
hours of life rather than correlating specific NIRS-values to the levels of S100beta, and there-
fore we cannot determine whether the S100beta levels measured in the SafeBoosC II study
were correlated to the NIRS-levels. We found no differences between the levels of S100beta
between the 4th quartile of cerebral hypoxia where the proportion of infants with severe IVH
was highest vesus the three lowest quartiles of cerebral hypoxia. The conflicting results of the
Table 2. Distributions of early and late adverse outcomes of cranial ultrasound, EEG variables, blood biomarkers, term diagnoses, and death
according to the burden of cerebral hypoxia within or below the 4th quartile.
Burden of hypoxia Quartile 1–3 Quartile 4
n = 123 n = 41 P-value *P-value OR (95% CI)
Cranial ultrasound
IVH 3–4 day 1–4 6/117 8/38 0.003 0.045 4.93 (1.59–15.30)
IVH 3–4 day 5–14 5/111 3/31 0.63 >0.95 2.27 (0.51–10.09)
IVH 3–4 at any time 11/117 11/39 0.003 0.045 3.77 (1.49–9.63)
Severe brain injury—any time 14/116 13/39 0.002 0.03 3.64 (1.53–8.69)
EEG variables time 64h
Burst-rate in the 1st quartile 21/103 12/28 0.015 0.23 2.93 (1.20–7.12)
Spectral edge frequency in the 1st quartile 15/99 5/27 0.67 >0.95 1.27 (0.42–3.88)
Plasma biomarkers difference between 6 and 64h
S100beta increase in 4th quartile 25/92 6/30 0.43 >0.95 0.67 (0.25–1.83)
BFABP increase in 4th quartile 24/89 8/31 0.90 >0.95 0.94 (0.37–2.39)
Neuroketal increase in 4th quartile 22/92 9/30 0.51 >0.95 1.36 (0.55–3.41)
Other major adverse outcome at term age
Necrotising enterocolitis 13/123 6/41 0.48 >0.95 1.45 (0.51–4.10)
Retinopathy of prematurity 18/123 4/41 0.43 >0.95 0.63 (0.20–1.98)
Bronchopulmonary dysplasia 52/104 14/27 0.86 >0.95 1.08 (0.46–2.51)
Death 18/123 14/41 0.006 0.09 3.03 (1.34–6.84)
Combined adverse outcome
Death or severe brain injury 28/117 20/41 0.003 0.045 3.03 (1.44–6.38)
Death or IVH 3 or 4 25/118 19/41 0.002 0.03 3.21 (1.51–6.84)
Values are given as numbers of events / numbers of infants investigated for event.
* P-value after Bonferoni correction for multiple comparisons.
https://doi.org/10.1371/journal.pone.0173440.t002
Cerebral hypoxia and early markers of brain injury
PLOS ONE | https://doi.org/10.1371/journal.pone.0173440 March 22, 2017 8 / 15
associations between S100beta and severe intracranial haemorrhages make the clinical value of
this biomarker questionable and further research is needed to evaluate whether S100beta is
suitable as an early biomarker of brain injury in extremely preterm infants.
BFABP, a brain-specific marker, is rapidly released from astrocytes as a response to ische-
mia, mechanical and oxidative brain damage [37]. BFABP was chosen as a potential biomarker
for brain injury in the SafeBoosC II trial, as it is known to rapidly increase in hypoxic-ischae-
mic stroke patients, and the high levels persist for several days after an event [37]. BFABP
might be a more sensitive marker of minor traumatic brain injury than S100beta [38] and is
elevated in patients with various neurodegenerative diseases[39]. A study involving 57 patients
undergoing cardiac surgery reports that neither S100beta nor BFABP had any clear prognostic
value for postoperative cognitive dysfunction [40]. We found no association between BFABP
and the burden of cerebral hypo- or hyperoxia–this might be because of the different nature of
the acute and severe local hypoxic-ischemia occurring in stroke patients compared to the
global relative cerebral hypoxia measured in the SafeBoosC II trial. Our study ads information
to the current litterateur of BFABP and brain injury–suggesting that there is no associations
between the burden of cerebral hypoxia at 72h of age and the increase of the levels of BFABP
from 6 to 64h of life. Further research on the associations between BFABP and brain injury in
extremely preterm infants is needed.
Neuroketals are compounds produced by free radical induced peroxidation of docosahexe-
noic acid, have been associated with white matter damage on MRI in preterm infants [41] and
are solely present in the brain [42]. Neuroketal is mainly released as a reaction to cerebral
Table 3. Distributions of early and late adverse outcomes of cranial ultrasound, EEG variables, blood biomarkers, term diagnoses, and death
according to the burden of cerebral hyperoxia within or below the 4th quartile.
Burden of hyperoxia Quartile 1–3 Quartile 4
n = 123 n = 41 P-value *P-value OR (95% CI)
Cranial ultrasound
IVH 3–4 day 1–4 11/116 3/39 0.74 >0.95 0.80 (0.21–3.01)
IVH 3–4 day 5–14 6/100 2/36 0.98 >0.95 0.92 (0.18–4.79)
IVH 3–4 at any time 17/117 5/39 0.79 >0.95 0.87 (0.30–3.52)
Severe brain injury—any time 21/117 6/38 0.76 >0.95 0.86 (0.32–2.31)
EEG variables time 64h
Burst-rate in the 1st quartile 27/95 3/36 0.17 >0.95 0.50 (0.19–1.35)
Spectral edge frequency in the 1st quartile 13/91 7/35 0.43 >0.95 1.50 (0.54–4.14)
Plasma biomarkers difference between 6 and 64h
S100beta increase in 4th quartile 24/93 7/29 0.86 >0.95 0.92 (0.35–2.41)
BFABP increase in 4th quartile 23/92 9/28 0.45 >0.95 1.42 (0.57–3.58)
Neuroketal increase in 4th quartile 25/93 6/29 0.5 >0.95 0.71 (0.26–1.95)
Other major adverse outcome at term age
Necrotising enterocolitis 17/123 2/41 0.12 >0.95 0.32 (0,07–1,45)
Retinopathy of prematurity 20/123 2/41 0.064 >0.95 0.26 (0.06–1.18)
Bronchopulmonary dysplasia 55/97 11/34 0.015 0.23 0.37 (0.16–0.83)
Death 26/123 6/41 0.36 >0.95 0.64 (0.24–1.68)
Combined adverse outcome
Death or severe brain injury 38/120 10/38 0.53 >0.95 0.77 (0.34–1.75)
Death or IVH 3 or 4 35/120 9/39 0.46 >0.95 0.73 (0.31–1.69)
Values are given as numbers of events / numbers of infants investigated for event.
* P-value after Bonferoni correction for multiple comparisons.
https://doi.org/10.1371/journal.pone.0173440.t003
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oxidative stress, and may due to their reactivity be involved in formation of protein cross-
links, which is a common feature in neurodegenerative diseases, where neuroketal is known to
be increased [43]. Neuroketal has been reported elevated in cerebrospinal fluid during the first
3 weeks of life infants with white matter damage on MRI performed at term equivalent age
[41]. We expected that the levels of neuroketal would be increased in the infants with cerebral
hyperoxia in the 4th quartile, but that was not the case. This might be explained by the early
measure of neuroketal– 6 to 64 hours of life and the fact that the level of cerebral hyperoxia in
the SafeBoosC phase II trial was low [14]. In addition neuroketal is still only an experimental
biomarker of cerebral injury and might not be a good marker of early acute brain injury in
extremely preterm infants. Whether neuroketal in the future can serve as a marker of later
white matter injury in extremely preterm infants remains to be determined.
Limitations
The explorative post hoc analysis of the SafeBoosC II trial data presents the association
between the early cerebral oxygenation and short-term adverse cerebral outcomes and death
in extremely preterm infants. However, this study has some limitations. Most importantly,
cranial ultrasound was conducted at pre-specified days of life, but the exact timing of IVH
grade III and PVHI and other severe brain damages is not available and therefore we cannot
know if cerebral hypoxia preceded IVH or vice versa. However, one small study in very pre-
term infants recently identified a significantly lower regional cerebral oxygenation during the
Fig 2. Risk for adverse outcomes for infants with a burden of cerebral hypoxia within or below the 4th quartile.
Odds ratio (OR) and 95% confidence interval.
https://doi.org/10.1371/journal.pone.0173440.g002
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early transition in infants who later developed IVH versus the infants who did not [44]. Simi-
larly, EEG was only recorded once. While the timing at 64 hours of age was expected to assess
the potential effects of the accumulated burden over the intervention period, finer details of
preceding or concurrent cerebral hypoxia could not be extracted, such as the relative signifi-
cance of longer periods of moderate hypoxia versus peaks of severe hypoxia. We did not collect
data on continuous blood pressure, arterial oxygen saturation, or CBF, which may have con-
tributed to both low cerebral NIRS values and severe brain damage [8,22,23].
The analyses are based on a dataset from our randomised clinical trial; therefore, the multi-
ple logistic regression models were adjusted for the stratification variables (centre and gesta-
tional age below 26 weeks), as well as the randomisation indicator (experimental vs. control
group). As the burden of hypoxia was reduced by 50% in the experimental group compared
with the control group [14], it was therefore not surprising that adjusting for the randomisa-
tion indicator did reduce the statistical significance of the burden of hypoxia. We do not think
that this changes the main conclusion of the study. On the other hand, the statistical signifi-
cance of the randomisation indicator means that the risk of severe brain injury or death in the
experimental group of the SafeBoosC-II trial was less in the experimental group than in the
control group when adjusted for a number of other factors. However, neither the composite
outcome nor the particular statistical analyses were specified in the trial protocol. This post-
hoc finding must therefore be interpreted conservatively. Finally, the 2-year follow up of the
infants included in the SafeBoosC II trial will further explore if cerebral hypoxia and/or the
intervention is related to patient-relevant outcomes such as psychomotor deficit. Larger
Fig 3. Risk for adverse outcomes for infants with a burden of cerebral hyperoxia within or below the 4th
quartile. Odds ratio (OR) and 95% confidence interval.
https://doi.org/10.1371/journal.pone.0173440.g003
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randomised clinical trials investigating possible patient-relevant benefits of continuous NIRS
monitoring in extremely preterm infants is needed before the method is implemented as stan-
dard care in this population.
Conclusions
Our analysis is currently the largest dataset published on cerebral oxygenation in extremely
preterm infants providing data on short-term neurological outcomes. The results support the
previous findings of associations between low cerebral oxygenation in extremely preterm
infants during the first days of life and EEG suppression, severe intracranial haemorrhage, and
death. However, our analyses are exploratory and we were unable to determine which came
first: cerebral hypoxia or severe intracranial haemorrhage. We did not find any evidence that
cerebral hyperoxia is associated with either death or severe brain damage. We found no associ-
ations between the burden of cerebral hypo- or hyperoxia and the three blood biomarkers
(S100beta, BFABP, and Neuroketal).
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